BDX - Becton Dickinson AI imaging app for bacterial growth analysis gets FDA nod

2023-05-16 12:24:39 ET

• The U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Becton, Dickinson and Company's ( NYSE: BDX ) BD Kiestra Methicillin-resistant Staphylococcus aureus (MRSA) imaging application, which uses artificial intelligence (AI) to interpret bacterial growth and release negative specimens with minimal human interaction.
• The company said the application uses AI to automate the traditionally labor- and time-intensive task of inspecting Petri dishes to decide if there is bacterial growth or not.
• "The use of this imaging application to automatically organize specimens in meaningful worklists helps use limited laboratory staff more efficiently and allows lab personnel to bring their expertise to bear on more critical and complex specimens," said Nikos Pavlidis, vice president and general manager for Diagnostics at BDX.
• BDX noted that the imaging application can be used with standalone BD Kiestra ReadA systems and track-based BD Kiestra laboratory automation solutions.

For further details see: